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Abstract
Purpose Despite the uncertain effects of anxiolytic
premedication with benzodiazepines on the quality of
postoperative recovery, perioperative benzodiazepine
administration is still a common practice in many
hospitals. We evaluated the effect of premedication with
midazolam on the quality of recovery in hospitalized
patients undergoing a laparotomy.
Methods We conducted a single-centre randomized
placebo-controlled, double-blinded clinical trial from
July 2014 to September 2015. We included 192 patients
aged [ 18 yr scheduled for elective laparotomy with a
planned postoperative stay of C three days. Participants
were randomized into two groups to receive either
midazolam 3 mg or sodium chloride 0.9% intravenously
as premedication prior to surgery. Patients were followed
up for up to one week after surgery. The primary outcome
was the Quality of Recovery-40 (QoR-40) score on
postoperative day (POD) 3. The secondary outcomes
included the QoR-40 score on POD 7, and the State-
Trait Anxiety Inventory, State-Trait Anger Scale,
Multidimensional Fatigue Inventory, and the Hospital
Anxiety and Depression Scale scores.
Results The mean (standard deviation) postoperative
QoR-40 scores on POD 3 were not significantly different
in the midazolam group compared with controls [166.4
(17.0) vs 163.9 (19.8), respectively; mean difference, 2.3;
95% confidence interval, - 2.9 to 8.4; P = 0.35]. There
were no between-group differences in any of the secondary
outcomes.
Conclusions Administration of midazolam as
premedication for laparotomy patients did not improve
the quality of recovery up to one week after surgery.
General prescription of midazolam as premedication can
be questioned and might only suit some patients.
Trial registration www.clinicaltrials.gov (NCT01993459);
registered 29 October, 2013.
Re´sume´
Objectif En de´pit des effets incertains d’une
pre´me´dication anxiolytique a` l’aide de benzodiaze´pines
sur la qualite´ de la re´cupe´ration postope´ratoire,
l’administration pe´riope´ratoire de benzodiaze´pine
demeure pratique courante dans bon nombre d’hoˆpitaux.
Nous avons e´value´ l’effet du midazolam en pre´me´dication
sur la qualite´ de la re´cupe´ration des patients hospitalise´s
subissant une laparotomie.
Me´thode Nous avons re´alise´ une e´tude clinique
monocentrique randomise´e, a` double insu et controˆle´e
par placebo entre les mois de juillet 2014 et septembre
2015. Nous avons inclus 192 patients aˆge´s de plus de 18
ans devant subir une laparotomie non urgente suivie d’un
se´jour postope´ratoire planifie´ d’au moins trois jours. Les
participants ont e´te´ randomise´s en deux groupes, le
premier recevant en pre´me´dication pre´-chirurgie une
solution intraveineuse de 3 mg de midazolam et le
second du chlorure de sodium 0,9 %. Les patients ont e´te´
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suivis pour une dure´e maximale d’une semaine apre`s la
chirurgie. Le crite`re d’e´valuation principal e´tait le score
QdR-40 (Qualite´ de la re´cupe´ration – 40) au 3e`me jour
postope´ratoire (JP3). Les crite`res d’e´valuation secondaires
comprenaient le score QdR-40 au JP7 ainsi que les scores
sur les e´chelles suivantes : le STAI (State-Trait Anxiety
Inventory – Questionnaire sur l’anxie´te´ chronique et
re´actionnelle), la STAS (State-Trait Anger Scale –
E´chelle de cole`re-e´tat et cole`re-trait), le MFI
(Multidimensional Fatigue Inventory – Inventaire
multidimensionnel de la fatigue) et le HADS (Hospital
Anxiety and Depression Scale – E´chelle d’anxie´te´ et de
de´pression en milieu hospitalier).
Re´sultats Les scores postope´ratoires moyens (e´cart type)
sur l’e´chelle QdR-40 au JP3 n’ont pas de´montre´ de
diffe´rence significative entre le groupe midazolam et le
groupe te´moin [166,4 (17,0) vs 163,9 (19,8),
respectivement; diffe´rence moyenne, 2,3; intervalle de
confiance 95 %, - 2,9 a` 8,4; P = 0,35]. Aucune diffe´rence
intergroupe n’a e´te´ observe´e dans les crite`res d’e´valuation
secondaires.
Conclusion L’administration de midazolam en
pre´me´dication chez les patients devant subir une
laparotomie n’a pas ame´liore´ la qualite´ de la
re´cupe´ration dans la premie`re semaine apre`s la
chirurgie. Une administration syste´matique de midazolam
en pre´me´dication peut eˆtre remise en question et pourrait
ne convenir qu’a` certains patients.
Enregistrement de l’e´tude www.clinicaltrials.gov
(NCT01993459); enregistre´e le 29 octobre 2013.
Despite the widespread use of benzodiazepines as
premedication based on their anxiolytic, amnestic, and
sedative effects, there is still debate whether they improve
the quality of postoperative recovery. Many patients
develop negative emotions when they are scheduled for a
surgical procedure. These may include anxiety, depression,
aggression, fatigue, and physical complaints. Anxiety is the
most well-known and prominent preoperative complaint.1-4
Preoperative anxiety can have adverse effects on the
perioperative course because it correlates with high
postoperative anxiety, increased postoperative pain,
increased need for analgesics, postoperative nausea and
vomiting (PONV), and prolonged hospital stay.5-7
Furthermore, it has been shown that preoperative anxiety
has a negative effect on the induction of anesthesia and
recovery.8,9
Anxiolytic premedication by benzodiazepines could
thus be a useful treatment for patients who suffer from
preoperative anxiety.10,11 Moreover, premedication with
midazolam lowers the incidence of PONV, which might
contribute to a better postoperative experience for
patients.12,13 Nevertheless, whether midazolam improves
the overall quality of postoperative recovery is unknown.14
For example, in two trials, one in ambulatory surgery
patients and the other in patients undergoing scheduled
inpatient surgery, lorazepam had no beneficial effect on the
quality of postoperative recovery and actually resulted in a
slower reduction in anxiety and increased aggression after
surgery.15,16 These results do not necessarily indicate that
all sedative premedication is unwarranted but do suggest
that the use of lorazepam might not always be appropriate.
As midazolam has anxiolytic properties of relatively
shorter duration, it could be a more appropriate
Timeline of the study. POD 0: baseline assessment preoperatively on the day of surgery (self-reported questionnaire); POD 1: first postoperative day after surgery, (self-
reported questionnaire); POD 3: third postoperative day (self-reported questionnaire); POD 7: seventh postoperative day (self-reported questionnaire); HADS, Hospital Anxiety
and Depression Scale; MFI, Multidimensional Fatigue Inventory; QoR-40: Quality of Recovery Score-40; STAI, State-Trait Anxiety Inventory; STAS, State-Trait Anger Scale.
Fig. 1 Timeline of the study. POD 0 = baseline assessment
preoperatively on the day of surgery (self-reported questionnaire);
POD 1 = first postoperative day after surgery, (self-reported
questionnaire); POD 3 = third postoperative day (self-reported
questionnaire); POD 7 = seventh postoperative day (self-reported
questionnaire); HADS = Hospital Anxiety and Depression Scale; MFI
= Multidimensional Fatigue Inventory; QoR-40 = Quality of
Recovery Score-40; STAI = State-Trait Anxiety Inventory; STAS =
State-Trait Anger Scale.
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benzodiazepine to improve the quality of postoperative
recovery.
Accordingly, the primary objective of this study was to
determine the effect of midazolam premedication on the
quality of recovery of patients up to one week after
surgery. We hypothesized that premedication with
midazolam for patients undergoing major surgery
(laparotomy) improves the quality of postoperative
recovery. The secondary objective was to assess the
effects of midazolam on anxiety, aggression, fatigue, and
depression in the postoperative period.
Analysed  (n=88)Analysed  (n=88)
Assessed for eligibility (n=796)
Excluded  (n=604)
Meeting exclusion criteria (n=285)
Declined to participate (n=218)
Logistic reasons (n=101)
Baseline data (n=96)
No data for analysis (n=1)
Unable to complete first measurement 
point. Administrative error (n=1)
Lost to follow-up (n=8)
Medical reason (n=2)
Patient deceased (n=1)
Patient refused (n=2)
Other reason (n=3)
No contact after discharge (n=2)
Lost report form (n=1)
Allocated to midazolam (n=97)
Received allocated midazolam (n=95)
Did not receive allocated midazolam (n=2)
Contra-indication for participation 
per order anesthesiologist (n=1)
Administration error (n=1)
Lost to follow-up (n=7)
Medical reason (n= 4)
Patient deceased (n=1)
Patient refused further participation after 
baseline measurement (n=1)
No contact after discharge (n=1)
Allocated to placebo (n=95)
Received allocated placebo (n=93)
Did not receive allocated placebo (n=2)
Contra-indication for participation 
per order anesthesiologist (n=1)
Administration error (n=1)
Allocation
Randomized (n=192)
Enrollment
Baseline data  (n=95)
Follow-Up
Analysis
Fig. 2 Flowchart showing patient flow up to one week following intention-to-treat.
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Methods
The Medical Ethical Committee of Erasmus University
Medical Centre (Rotterdam, The Netherlands) together
with the Netherlands Central Committee on Research
involving Human Subjects approved the study protocol on
18 June 2013. The trial was registered prior to participant
enrolment at clinicaltrials.gov (NCT01993459; date of
registration: 29 October, 2013). All participants provided
written informed consent prior to enrolment in the study.
Study population
Between 11 July 2014 and 28 September 2015, 192
consecutive patients were recruited from the hospital’s
departments of general surgery, gynecology, and urology.
Inclusion criteria were the requirement for laparotomy,
planned postoperative hospital stay for C three days, and
age C 18 yr. There was no upper age limit for inclusion.
Exclusion criteria for participants were any
contraindication to midazolam administration, intellectual
disability, insufficient command of the Dutch language, or
current use of psychopharmaceutical drugs (e.g.,
antidepressants, antipsychotics, anticonvulsants, and
benzodiazepines).
Study design
Participants were randomized in a parallel group design
with varying block sizes (8-10-12). The allocation ratio
was 1:1, to either midazolam or equal volume of sodium
chloride (NaCl) 0.9% (placebo). An independent
statistician performed the randomization with a
computer-generated table. Upon inclusion, patients were
assigned successive numbers. Independent nurses with
access to the randomization table prepared the study
medication. The researchers, patients, and all other
healthcare professionals were blinded to the treatment
allocation.
Intervention
Figure 1 shows a timeline of all study procedures. All
elective surgery patients received written information
about the study at least one week before surgery. After
admission on the ward, a member of the research group
obtained written informed consent from eligible patients.
While waiting for surgery, patients completed the first set
of questionnaires (preoperative, postoperative day [POD]
0). In the preoperative holding area, the independent
recovery nurses prepared the medication according to the
group assignment document. Blinding for patients was
achieved by preparation of the various transparent fluids in
identical syringes. Midazolam was diluted in NaCl 0.9% to
1 mgmL-1. Another nurse blinded to the treatment
condition injected the single dose of 3 mL midazolam
solution or 3 mL NaCl 0.9% iv 45-60 min before induction
of anesthesia. No additional premedication or other
benzodiazepine administration was allowed. Postoperative
care was carried out according to our institution’s
(Enhanced Recovery after Surgery [ERAS]) protocol.
Patients completed questionnaires after surgery on
postoperative day (POD) 1, POD 3, and POD 7. The
healthcare professionals who administered the
questionnaires were blinded to the treatment allocation.
Assessment of outcomes
Primary outcome
The primary outcome, quality of recovery after surgery,
was measured with the 40-item Quality of Recovery Score-
40 (QoR-40) on POD 3.17,18 The Qor-40 contains five
scales assessing physical comfort, emotional state, physical
independence, psychological support, and pain. All items
are scored on a five-point Likert scale, and the QoR-40
score is calculated as the total sum of the scores: the higher
the score, the higher the quality of recovery (minimum
score 40, maximum score 200). The QoR-40 has a good
internal consistency (Cronbach’s a = 0.93).18
Secondary outcomes
Secondary outcomes included the QoR-40 on POD 7,
anxiety, fatigue, depressive mood, and aggression. All
questionnaires were validated Dutch versions with high
internal consistencies.19-23 Anxiety was measured at POD 1
and 7 with the State-Trait Anxiety questionnaire (STAI)
measuring both trait anxiety (general feeling of anxiety)
and state anxiety (current feeling of anxiety).19 Both
questionnaires have two 20-item scales. A higher score
signifies a higher level of anxiety (score range 20-80).
Fatigue was measured with the Multidimensional Fatigue
Inventory (MFI) measuring general fatigue, physical
fatigue, mental fatigue, reduced motivation, and reduced
activity. 20 Each section has four items. A higher total score
indicates increased fatigue (score range 20-100). The
Hospital Anxiety and Depression Scale (HADS) was used
to measure depressive moods and consists of two 7-item
scales, one measuring depression and one measuring
anxiety.21,22 A higher total score indicates higher degrees
of depressive moods (score range 0-21). Aggression was
measured with the State-Trait Anger Scale (STAS),
measuring both state aggression (at this moment) and
trait aggression (general feeling).23 Both parts have ten-
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item scales. A high STAS indicates high levels of
aggression (score range 10-40).
Demographic measures were assessed at baseline and
during the timeline of the study. During surgery, we
recorded a number of perioperative parameters (e.g., heart
rate, blood pressure, temperature, saturation, duration of
surgery, complications).
Statistical analysis
Sample size calculations were based on the primary
outcome variable, i.e., QoR-40 at POD 3. According to
Myles et al. and our previous study, the preoperative mean
(standard deviation [SD]) of QoR-40 is 183 (17).15,18 We
expected that the clinical effect would equal half of the
standard deviation (i.e., 0.5 9 17 = 8.5). Therefore, to get a
clinically relevant difference, a positive mean difference
between the midazolam and placebo group of at least 8.5
would be necessary. The two-sided alpha level was fixed at
0.05, with a beta of 0.10. Based on these data, a minimum
number of 86 in each group was required. We expected a
dropout rate of 10% and thus increased the total number of
patients required for inclusion to 192 (96 in each group)
accordingly.
Secondary outcome variables were expected to
correlate, and with the number of independent
measurement scales (dimensions) being eight, we applied
a Bonferroni correction to adjust for multiplicity.
Therefore, for statistical significance of the secondary
outcome, variables were assessed at a two-sided alpha of
0.05/8 (P\ 0.006).
Data were analyzed according to an intention-to-treat
principle. According to previous work,15 we applied a
robust regression analysis (MM estimation) for our primary
and secondary outcome data to allow for non-normal
distribution of the outcome variables and for
heteroskedasticity.24,25 To correct for potential bias, we
adjusted our analysis for the baseline imbalance of the
corresponding outcome variable and sex. Demographical
categorical data were tested with the Pearson Chi square
test. Demographical continuous data were analyzed with
the Student’s t-test for independent observations.
We used SAS version 9.2 (SAS Institute Inc, Cary, NC,
USA) for the regression analyses and SPSS software
version 21.0 (SPSS Institute, Chicago, IL, USA) for all
other analyses.
Results
Study population
A total of 796 patients were assessed for eligibility, of
which 192 were randomized to either the midazolam (n =
97) or NaCl 0.9% (n = 95) group (Fig. 2). There were 285
patients who met one or more of the exclusion criteria, 218
patients refused to participate, and 101 patients were
excluded for logistic reasons (e.g., contact isolation or too
short an interval between eligibility assessment and start of
the surgical procedure).
In retrospect, the baseline measurements were not
registered correctly for one patient in the midazolam
group where POD 0 data were lacking. In the placebo
group, one patient refused further participation after POD 0
assessment because of the outcome of the surgery (non-
resectable tumour). Thus, for the final analysis, the
midazolam group included 96 participants with available
POD 0 data, and in the placebo group, data were available
for 95 participants (Fig. 2).
During the postoperative study period, there was little
lost to follow-up at POD 3 and/or at POD 7, including both
cases mentioned above. The difference in the lost to
follow-up between the study groups for any of the
measurements was not statistically significant. In the
midazolam group, we lost eight participants during
follow-up leaving 88 participants at POD 7 (i.e., 96 - 8
= 88). In the placebo group, we lost seven participants
during follow-up leaving 88 participants at POD 7 (i.e., 95
- 7 = 88).
General characteristics
Table 1 provides the baseline patient characteristics.
Overall, there were no differences in general patient
characteristics between the two study arms (Table 1). We
found no differences in adverse events (e.g., hypoxia,
delirium, unplanned intensive care unit-admission, death)
between the groups. All endpoints were skewed non-
normally distributed and all questionnaires had outliers in
the data.
Primary outcome
Postoperative mean (standard deviation) QoR-40 scores
were not significantly better in the midazolam group at
POD 3 compared with controls [166.4 (17.0) vs 163.9
(19.8), respectively; mean difference, 2.3; 95% confidence
interval [CI], - 2.9 to 8.4; P = 0.35]. Table 2 shows the
mean QoR-40 scores for both groups at POD 0 and POD 3.
In both groups, the mean scores were high at all time
points. After surgery, mean values declined in both groups.
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Secondary outcomes
Neither the STAI-State and STAI-Trait showed any
significant differences between groups on POD 1
(Table 3). At POD 7, there were no between-group
differences in the mean QoR-40 score (mean difference,
6.7; Bonferroni-adjusted 95% CI, - 0.1 to 15.5; unadjusted
P value = 0.007, which did not meet our pre-specified
significance level of P\ 0.006) (Table 4).
After one week, there were no significant between-group
differences in the postoperative HADS-Anxiety scores
(Table 4). The MFI (assessing fatigue) was also not
different between groups as were the STAS-State, STAS-
Trait, and HADS-Depression scores. Eleven patients in the
midazolam group and ten patients in the placebo group
filled in the POD 7 questionnaire after hospital discharge.
Discussion
This study showed that midazolam as premedication did
not improve the quality of postoperative recovery in the
first week after laparotomy. Although we observed a
difference in mean QoR-40 score of 6.7 at POD 7, at the
time the present study was designed, a minimal clinically
important difference (MCID) for the QoR-40 score was not
defined. In our sample size calculation, we had assumed a
clinically relevant difference when the mean difference
was C 8.5. We based this value on previous studies that
used the QoR-40.15,18 After completing our study, Myles
et al. published a new MCID for the QoR-40 stating that a
change of 6.3 points should be considered a clinically
important improvement.26 We observed a Bonferroni-
adjusted 95% CI of - 0.1 to 15.5 for the mean
difference, which includes the new MCID value, and
therefore there could have been be a clinically relevant
improvement in the quality of recovery in the midazolam
group at POD 7. Nevertheless, we hesitate to relate our
findings to this new MCID since our study was not
designed based on POD 7 or on this new MCID value.
Future research should be designed and powered for a
longer follow-up using this new MCID value of 6.3.
When designing this trial after our previous study in
day-surgery patients,15 we hypothesized that hospitalized
patients who undergo a laparotomy would have higher
baseline scores for anxiety, depression, fatigue, and
aggression and would have lower baseline quality of
recovery scores. Nevertheless, baseline scores were
comparable to day-surgery patients. In addition, there
was no clinically relevant beneficial effect of
premedication on postoperative depression, aggression,
and fatigue. We did see a bigger decline in QoR-40 scores
after laparotomy compared with day-surgery.15 This result
was expected since surgery by laparotomy is considered
more debilitating than day-surgery. After the first
postoperative day, quality of recovery increased for all
patients. This may be because laparotomy patients (52% [n
= 99] of whom had cancer) see their surgery not as
Table 1 Patient characteristics at baseline
Intervention
Midazolam
(n = 96)
NaCl 0.9%
(n = 95)
Demographic
Sex, n (%)
Male 58 (59.8) 62 (65.3)
Age, mean (SD) 56.5 (15.0) 57.5 (12.9)
Educational levela, n (%)
Low 25 (26.0) 33 (34.7)
Mid-level 63 (65.6) 49 (51.6)
High 8 (8.3) 13 (13.7)
Marital statusb, n (%)
Single 30 (31.3) 18 (18.9)
Together 66 (68.8) 77 (81.1)
Religion (are you religious?), n (%)
Yes 45 (46.9) 49 (51.6)
Employment, n (%)
Yes 38 (39.6) 50 (52.6)
Clinical
Weightc, mean (SD) 79.7 (16.3) 79.8 (16.1)
Heightd, mean (SD) 174.4 (9.6) 175.0 (10.1)
Heart ratee, mean (SD) 79.6 (17.0) 75.9 (14.1)
Had surgery before, n (%)
Yes 89 (91.8) 84 (88.4)
ASAf, n (%)
ASA I 8 (8.2) 8 (8.4)
ASA II 43 (44.3) 46 (48.4)
ASA III 43 (44.3) 41 (43.2)
ASA IV 3 (3.1) 0 (0)
Type of surgery, n (%)
General surgery 88 (90.7) 89 (93.7)
Gynaecology 10 (6.2) 4 (4.2)
Urology 5 (3.1) 2 (2.1)
Oncological surgery, n (%)
Yes 44 (45.4) 53 (55.8)
NaCl = sodium chloride; SD = standard deviation. Values represent n
(%) or mean (SD) as indicated.
a Low: no education; elementary school; preparatory middle-level
vocational education. Mid-level: middle-level vocational education;
higher general continued education; higher vocational education.
High: preparatory university education; university education.
b Single: unmarried; divorced; widowed. Together: married; living
together. c Weight: body weight in kg. d Height: body length in cm.
e Heart rate: beats per minute. f Risk classification according to the
American Society of Anesthesiology (ASA).
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disabling but as a potential cure. One week after surgery,
the quality of recovery was even higher showing that the
patients were recovering from surgery (ERAS protocol)
and were almost ready for discharge.
Grant et al.12 Ahn et al.13 and Mijderwijk et al.27
described reduced PONV after perioperative administration
of midazolam. These effects may improve the quality of
recovery. Maurice-Szamburski et al. found no
improvement in self-reported experience after
premedication with oral lorazepam before elective
surgery.16 Also, Mijderwijk et al. showed that
premedication with lorazepam in day-surgery settings had
no beneficial effect on quality of recovery.15 Patients
treated with lorazepam showed even more postoperative
anxiety and aggression. Next to a rebound effect,28 their
results could be explained by the fact that day-surgery
induces less anxiety than major procedures. We chose to
study a population with a longer postoperative recovery in
the hospital. By only including people who had a
postoperative stay of at least three days, all perioperative
medication lost its pharmacological effect during the
hospital stay, and all patients had to deal with their
psychological symptoms under the same conditions.29 We
did not find any symptoms of paradoxical effects or a
rebound phenomenon due to midazolam.
The indication of premedication for the preoperative
setting may be less important for non-day-surgery.30
Studies showing a positive effect are dated from 1980 to
2000. Healthcare has significantly changed over time.
Recently, it was shown that sedative premedication before
surgery was no more effective than a placebo, owing to the
moderate level of anxiety experienced by patients.31 A low
preoperative anxiety level in patients might explain the
small difference in quality of postoperative recovery in this
study.31
Our findings should be interpreted in the context of our
study methodology and its limitations. We performed our
clinical trial in a single-centre setting and focused only on
postoperative outcomes. Preoperative outcomes were not
included in this study.
Quality of postoperative recovery was measured using
the QoR-40 questionnaire.32 The QoR-40 (Dutch version)
is a translated, well-validated questionnaire but it remains
difficult to extrapolate our result to other populations.
Expressing negative emotions can be culturally
determined, which makes it difficult to compare these
aspects between different ethnic groups.33 Taking into
account differences in anxiety and emotions before and
after surgery for males and females, we have adjusted our
outcomes for sex.34 One limitation of studies using
questionnaires such as the QoR-40 is the possibility of a
floor/ceiling-effect.35 While we had no patients scoring the
highest and lowest QoR-40 scores, we nonetheless tried to
limit the impact of this phenomenon by correcting for the
baseline measurement. We did not measure QoR-40 scores
at POD 1. In our opinion, POD 3 was more appropriately
timed for major surgery patients. Furthermore, we think
that the quality of recovery on POD 3 is a good predictor of
the total length of stay after major surgery, which might
also be of economical and logistical interest. Although
there is no evidence of a training effect for the
questionnaires used in this study, it could theoretically
bias the outcome data.
We chose midazolam for its proven anxiolytic
properties, relatively short duration of action, positive
effects on anesthesia, and being the most prescribed
premedication drug.4,11 Because we used midazolam in a
monitored situation, we could account for possible
unpredictable effects or paradoxical reactions.36
Ideally the administration of midazolam, or any
premedication, should be weight dependent. The standard
dose for premedication with oral midazolam in the
Erasmus Medical Centre is 7.5 mg. With a bioavailability
of 40% of the oral dose we therefore administered 3 mg
midazolam intravenously in our study group.37 Higher
doses might have adverse effects, which would negatively
affect the preoperative period. Normally premedication is
given orally. With intravenous administration, we wanted
to avoid variations in drug resorption kinetics and
effectiveness.38 Overall, the timing of premedication and
Table 2 Changes in primary outcome (QoR-40 score)a three days after surgery
Midazolam
Mean (SD) [n]
NaCL 0.9%
Mean (SD) [n]
Mean (diff)b 95% CI X2 P*
Lower Upper
Baseline assessment POD 0 179.9 (15.9) [96] 179.7 (17.6) [95] NA NA NA NA NA
Third day after surgery POD 3 166.4 (17.0) [91] 163.9 (19.8) [91] 2.3 - 2.9 8.4 0.9 0.35
CI = confidence interval; NaCl = sodium chloride; POD = postoperative day.
a Quality of Recovery-40 min-max score: 40-200. b Mean difference, condition coded as 0 (placebo) and 1 (midazolam). *P values are rounded
upwards. Tested by robust regression analysis (adjusted for baseline and sex).
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the start of anesthesia induction in our study reflect
common practice.11
Anesthesia techniques were not standardized for all
patients. Blinding for the treating anesthesiologist was hard
to accomplish in some patients because of the sedative
effect of midazolam. This may have caused them to
administer less hypnotic anesthetics (i.e., propofol) in
already sedated patients. Nevertheless, we did not find
differences in the anesthetic regimens and believe that
differences in outcome are best explained by the use of
midazolam. We did not match our participants. By
randomizing, it is assumed that all confounders are
distributed equally in both groups. Therefore, we did not
correct for different type of laparotomies, anesthesia
techniques, or other surgical factors. Anxiety might be
affected by factors like education level, marital status, and
employment status. Therefore, we analyzed our two groups
for possible differences after randomization. Despite a
somewhat unbalanced distribution, we found no
statistically significant differences between the two
groups. We could not include 101 patients for logistic
reasons. We have no reason to believe this led to selection
bias because we included consecutive patients.
Table 3 Changes in secondary outcome variables one day after surgery
Midazolam NaCl 0.9% Mean (diff)a 95% CIb X2 Pb*
POD 0
Mean (SD)
n=96
POD 1
Mean(SD)
n=94
POD 0
Mean(SD)
n=95
POD 1
Mean(SD)
n=93
Lower Upper
Anxiety
STAI-State 38.0 (9.1) 32.1 (9.0) 40.7 (9.7) 34.7 (8.9) 0.1 - 3.6 1.4 0.78 0.38
STAI-Trait 31.1 (7.1) 29.8 (8.8) 32.0 (7.1) 28.6 (6.8) 2.2 - 0.7 2.8 1.4 0.24
CI = confidence interval; NaCl = sodium chloride; POD = postoperative day; SD = standard deviation; STAI = State-Trait Anxiety Inventory.
a Mean difference, condition coded as 0 (placebo) and 1 (midazolam). bConfidence intervals and P values have not been adjusted for multiple
comparisons. *P values are rounded upwards. Tested by robust regression analysis (adjusted for baseline and sex) using MM estimation.
Table 4 Changes in secondary outcome variables over one week
Score (min-max) Midazolam NaCl 0.9% Mean (diff)a 95% CIsb X2 Pb*
POD 0
Mean (SD)
n = 96
POD 7
Mean (SD)
n = 88
POD 0
Mean (SD)
n = 95
POD 7
Mean (SD)
n = 88
Lower Upper
QoR-40 40-200 179.9 (15.9) 172.9 (15.5) 179.7 (17.6) 166 (18.4) 6.7 2.1 13.3 7.32 0.007#
Anxiety
STAI-State 20-80 38.0 (9.1) 31.6 (8.8) 40.7 (9.7) 34.8 (10.6) - 0.5 - 4.9 1.2 1.43 0.23
STAI-Trait 20-80 31.2 (7.1) 29.1 (7.6) 32.0 (7.1) 30.0 (7.9) 0.1 - 1.4 2.0 0.13 0.72
HADS 0-21 4.0 (3.3) 2.4 (2.7) 4.8 (3.4) 3.6 (3.6) - 0.3 - 1.4 - 0.1 4.0 0.05
Fatigue
MFI 20-100 53.8 (18.2) 56.6 (16.5) 49.9 (17.5) 60.1 (16.6) - 7.4 - 10.3 0.1 3.71 0.05
Aggression
STAS-State 10-40 10.5 (2.2) 10.8 (3.1) 10.3 (0.9) 10.7 (1.8) - 0.1 - 0.1 0.1 0.59 0.44
STAS-Trait 10-40 13.6 (4.3) 13.2 (4.1) 13.0 (2.8) 13.4 (3.1) - 0.8 - 1.3 0.1 2.72 0.10
Depression
HADS 0-21 3.4 (2.7) 3.5 (3.3) 3.6 (3.3) 4.6 (4.3) - 0.8 - 1.4 0.4 1.22 0.27
CI = confidence interval; HADS = Hospital Anxiety and Depression Scale; MFI = Multidimensional Fatigue Inventory; NaCl = sodium chloride;
POD = postoperative day; QOR-40 = quality of recovery 40; SD = standard deviation; STAI = State-Trait Anxiety Inventory; STAS = State-Trait
Anger Scale.
a Mean difference condition coded as 0 (placebo) and 1 (midazolam). b Confidence intervals and P values have not been adjusted for multiple
comparisons *P values are rounded upwards. #No significant difference, P for significance after Bonferroni correction = P\ 0.006. Tested by
robust regression analysis (adjusted for baseline and sex) using MM estimation.
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Based on several recent publications, some of the
(especially older) patients may have much more benefit
from a benzodiazepine-free anesthesia to avoid
postoperative delirium and postoperative cognitive
dysfunction.39-41 Both states are related with higher
morbidity and mortality after surgery.42 Thus, clear
indications are needed for when to administer
benzodiazepines as premedication because it might not
suit all patients. In this study, no conclusions could be
made on the causality of benzodiazepine administration
and the incidence of delirium because the incidence of
delirium was too low (n = 1). Based on the now available
evidence, future research should focus on patients with low
preoperative QoR-40 or high anxiety levels to investigate
whether premedication would improve their postoperative
quality of recovery. Outcome parameters to measure
should be linked to the ERAS-milestones (e.g.,
mobilization, oral intake). Furthermore, the sedative
(side-) effects of benzodiazepine deserve more attention
(e.g., time to extubation, postoperative delirium).
Conclusion
Our study did not find an improved quality of recovery
after premedication with midazolam in adult hospitalized
patients undergoing a laparotomy. These findings are in
line with those from others, and raise questions as to the
general use of midazolam for anesthetic premedication.
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